Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Escalating 225Ac-LNC1011 in mCRPC
NCT07363486Phase 2Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 225Ac-LNC1011 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The First Hospital of Fujian Medical University. Started Apr 2025; status: recruiting.
02
Drugs
225Ac-LNC1011
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07363486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363486.